[Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology].

摘要: Colorectal liver metastases are detected in 15-20% of patients at the time diagnosis primary tumor, they develop an additional 20-30% during further course disease. Radical resection enables 5-year survival rates 30-50%. Resectability may be increased by surgical techniques including two-stage hepatectomy and portal vein embolization. Furthermore, modern chemotherapy various combinations oxaliplatin, irinotecan, bevacizumab, cetuximab has led to secondary resectability correlating response which up 80%. Changes hepatic histology such as sinusoidal obstruction (e.g. following oxaliplatin) or steatohepatitis irinotecan) have been described. Individually, this increase risk subsequent resection. As today role neoadjuvant for resectable lesions not definitively confirmed.